Total Payments
$107,778
2024 Payments
$11,000
Companies
9
Transactions
69
Payment Breakdown by Category
Research$81,581 (75.7%)
Consulting$19,792 (18.4%)
Travel$4,118 (3.8%)
Food & Beverage$1,889 (1.8%)
Other$390.00 (0.4%)
Education$8.35 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $81,581 | 15 | 75.7% |
| Consulting Fee | $19,792 | 7 | 18.4% |
| Travel and Lodging | $4,118 | 21 | 3.8% |
| Food and Beverage | $1,889 | 23 | 1.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $390.00 | 2 | 0.4% |
| Education | $8.35 | 1 | 0.0% |
Payments by Type
Research
$81,581
15 transactions
General
$26,197
54 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $85,604 | 45 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $19,557 | 10 | $0 (2019) |
| Novo Nordisk AS | $1,843 | 5 | $0 (2018) |
| Medtronic MiniMed, Inc. | $250.00 | 1 | $0 (2018) |
| Dexcom, Inc. | $217.05 | 2 | $0 (2022) |
| Tandem Diabetes Care, Inc. | $99.73 | 1 | $0 (2018) |
| Amgen Inc. | $99.43 | 1 | $0 (2017) |
| Novo Nordisk Inc | $99.25 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,000 | 2 | Eli Lilly and Company ($11,000) |
| 2023 | $795.01 | 1 | Eli Lilly and Company ($795.01) |
| 2022 | $36,273 | 3 | Eli Lilly and Company ($36,161) |
| 2021 | $636.91 | 3 | Eli Lilly and Company ($636.91) |
| 2020 | $9,949 | 21 | Eli Lilly and Company ($9,949) |
| 2019 | $23,971 | 17 | Eli Lilly and Company ($23,612) |
| 2018 | $9,318 | 9 | SANOFI-AVENTIS U.S. LLC ($4,942) |
| 2017 | $15,837 | 13 | SANOFI-AVENTIS U.S. LLC ($14,265) |
All Payment Transactions
69 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $10,800.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | ||||||
| 03/01/2024 | Eli Lilly and Company | — | — | In-kind items and services | $199.89 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | ||||||
| 05/22/2023 | Eli Lilly and Company | — | — | In-kind items and services | $795.01 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | ||||||
| 11/29/2022 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $111.71 | General |
| Category: Endocrinology | ||||||
| 07/26/2022 | Eli Lilly and Company | — | — | In-kind items and services | $17,942.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | ||||||
| 05/31/2022 | Eli Lilly and Company | — | — | In-kind items and services | $18,219.00 | Research |
| Study: A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | ||||||
| 04/09/2021 | Eli Lilly and Company | — | — | In-kind items and services | $351.93 | Research |
| Study: A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | ||||||
| 04/08/2021 | Eli Lilly and Company | — | — | In-kind items and services | $31.03 | Research |
| Study: A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN STUDY PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS PREVIOUSLY TREATED WITH MULTIPLE DAILY INJECTION THERAPY | ||||||
| 01/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $253.95 | Research |
| Study: A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | ||||||
| 10/27/2020 | Eli Lilly and Company | — | — | In-kind items and services | $359.38 | Research |
| Study: A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | ||||||
| 07/24/2020 | Eli Lilly and Company | — | — | In-kind items and services | $2,182.42 | Research |
| Study: A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | ||||||
| 03/24/2020 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $52.90 | General |
| 03/24/2020 | Eli Lilly and Company | — | Food and Beverage | Cash or cash equivalent | $15.97 | General |
| 03/04/2020 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $437.39 | General |
| 03/03/2020 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $248.00 | General |
| 03/03/2020 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $240.00 | General |
| 03/03/2020 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $157.00 | General |
| 03/03/2020 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $123.50 | General |
| 03/03/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $93.50 | General |
| 03/03/2020 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $65.00 | General |
| 03/03/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $33.15 | General |
| 03/03/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $23.80 | General |
| 03/03/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $23.38 | General |
| 03/03/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $10.29 | General |
| 03/03/2020 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $7.96 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO HUMALOG IN ADULTS WITH TYPE 1 DIABETES USING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION | Eli Lilly and Company | $19,231 | 1 |
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $18,219 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $17,942 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | Eli Lilly and Company | $11,795 | 3 |
| A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $4,006 | 2 |
| A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN STUDY PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS PREVIOUSLY TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $3,790 | 2 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND COMPARISON OF LY900014 AND FIASP, BOTH IN COMBINATION WITH BASAL INSULIN IN ADULTS WITH TYPE 1 DIABETES PROTO COMPARE | Eli Lilly and Company | $3,450 | 1 |
| A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $2,534 | 2 |
| A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | Eli Lilly and Company | $613.33 | 2 |
About Dr. Michael Dempsey, M.D
Dr. Michael Dempsey, M.D is a Endocrinology, Diabetes & Metabolism healthcare provider based in Rockville, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730197229.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Dempsey, M.D has received a total of $107,778 in payments from pharmaceutical and medical device companies, with $11,000 received in 2024. These payments were reported across 69 transactions from 9 companies. The most common payment nature is "" ($81,581).
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Rockville, MD
- Active Since 08/03/2006
- Last Updated 11/20/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1730197229
Products in Payments
- PRALUENT (Drug) $15,986
- SOLIQUA (Drug) $3,221
- Tresiba (Drug) $1,303
- SOLIQUA 100/33 (Drug) $350.00
- Dexcom G6 Transmitter (Medical Supply) $111.71
- Dexcom G5 Mobile CGM System (Device) $105.34
- t-slim insulin pump (Device) $99.73
- Prolia (Biological) $99.43
- Victoza (Drug) $76.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Rockville
Helena Rodbard, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1.3M
Endocrinology, Diabetes & Metabolism $1.3M
Dr. David Brown, Md, Phd, MD, PHD
Endocrinology, Diabetes & Metabolism — Payments: $772,094
Endocrinology, Diabetes & Metabolism $772,094
Dr. Jie He, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $28,893
Endocrinology, Diabetes & Metabolism $28,893
Monika Mannan, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $7,501
Endocrinology, Diabetes & Metabolism $7,501
Linda Nguyen, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $2,797
Endocrinology, Diabetes & Metabolism $2,797
Dr. Edward Movius, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $2,197
Endocrinology, Diabetes & Metabolism $2,197